HBIG provides temporary (i.e.,3–6 months) protection from HBV infection and is typically used asPEP as an adjunct to hepatitis B vaccination for previously unvaccinatedpersons or for persons who have not responded to vaccination. This evidence concerns the gene PPIB and hepatitis A virus infection.